Acute Blood Pressure Management in Intracerebral Hemorrhage

Target Blood Pressure

Aim for a systolic blood pressure (SBP) of 140 mmHg (acceptable range 130‑150 mmHg) within the first hour of treatment in patients presenting with acute ICH and an initial SBP of 150‑220 mmHg; do not lower SBP below 130 mmHg because this is potentially harmful. Class III: Harm recommendation. 1

Initiate blood‑pressure lowering within 2 hours of symptom onset to maximize reduction in hematoma expansion and improve functional outcomes. Earlier treatment (≤2 h) is linked to reduced hematoma growth and better 90‑day outcomes. 1
A subgroup analysis of the ATACH‑2 trial showed that intensive BP lowering within 2 hours of ICH onset lowered the risk of hematoma expansion and improved outcomes compared with later initiation. 1

Never lower SBP below 130 mmHg; doing so is associated with worse outcomes and increased mortality (Class III: Harm). 1
Aggressive lowering below 130 mmHg in patients with moderate‑severity ICH and presenting SBP > 150 mmHg is potentially harmful, as demonstrated in the ATACH‑2 and INTERACT2 trials. 1

Use rapid‑onset, short‑duration intravenous agents to allow smooth titration and sustained BP control. 1
Intravenous nicardipine is preferred as a first‑line agent because of its ease of titration and reliable BP control. This choice is supported by ATACH‑2 trial data. 1
Intravenous labetalol is an acceptable alternative when no contraindications exist.
Avoid glyceryl trinitrate (GTN); venous vasodilation may impair hemostasis and raise intracranial pressure. 1

Minimize BP variability: high SBP variability during the first 24 hours independently predicts death and severe disability at 90 days. Post‑hoc analysis of INTERACT2 showed a linear relationship between the standard deviation of SBP and poor outcomes. 1

Continue smooth, sustained BP control for at least 7 days after ICH onset, keeping SBP within the 130‑150 mmHg range to limit variability‑related harm. 1

Patients with Glasgow Coma Scale < 5 or massive ICH were largely excluded from major trials; evidence for intensive BP lowering in these groups is limited. 1
The INTERACT2 and ATACH‑2 trials enrolled mainly patients with mild‑to‑moderate ICH (median hematoma volume ≈ 11 mL) in deep brain locations; the modest benefit observed may be attenuated in elderly patients with multiple comorbidities. 2

Do not resume long‑term antithrombotic therapy for secondary stroke prevention in patients with a history of primary ICH, unless the individual has a relatively low risk of recurrent ICH (deep hemorrhages) and a high risk (> 7 %/year) of thromboembolic events (e.g., mechanical heart valve, CHADS₂ ≥ 4). [3][4]

All statements are supported by the cited evidence.

The American Heart Association/American Stroke Association recommends targeting a systolic blood pressure of 140 mm Hg within 1 hour of treatment initiation for patients with spontaneous intracerebral hemorrhage presenting with systolic blood pressure between 150-220 mm Hg, with a maintenance range of 130-150 mm Hg 5
The primary target is to achieve systolic BP <140 mm Hg within 1 hour of initiating treatment, with an acceptable range of 130-150 mm Hg 5, 6
Treatment should be initiated within 2 hours of symptom onset to reduce hematoma expansion and improve functional outcomes 5
The American Heart Association/American Stroke Association guidelines provide evidence for this approach, synthesizing data from INTERACT2 and ATACH-2 trials, which establishes 140 mm Hg as the optimal lower threshold 5

The American Heart Association/American Stroke Association recommends avoiding lowering systolic blood pressure below 130 mm Hg, as this is potentially harmful and associated with worse outcomes, with a Class III: Harm recommendation 5
Cerebral perfusion pressure should be maintained ≥60 mm Hg at all times 6, 7

The American Heart Association/American Stroke Association recommends using agents with rapid onset and short duration to facilitate smooth titration and minimize BP variability, with intravenous nicardipine as a preferred agent 5, 7

Continuous BP monitoring via arterial line is recommended for patients requiring continuous IV antihypertensives, with reassessment of neurological status every 15 minutes during active BP reduction 6
BP variability should be avoided, as it is independently associated with poor outcomes 5

The American Heart Association/American Stroke Association recommends a long-term target blood pressure of <130/80 mm Hg for secondary prevention of ICH recurrence 8, 6
Hypertension is the most important modifiable risk factor for ICH recurrence, with recurrence rates of 2.1-3.7% per patient-year 8
The PROGRESS trial demonstrated that BP lowering significantly reduced risk of first ICH and recurrent ICH 8